Stonvex publishes market data and research only. Not investment advice. Not a registered investment advisor. Read disclaimer.

SMMT

Live52w low +31.2%

Annual Quarterly

Core line items from SMMT's most recent SEC filings (10-K / 10-Q via EDGAR XBRL). Last 4 reporting periods.

Annual Quarterly

Entity: Summit Therapeutics Inc.·Source: SEC EDGAR companyfacts·Next-Q consensus from Finnhub

Metric	Q3 2026 (Est.) Expected 2026-08-10	Annual 2024 2024-12-31	Q3 2024 2024-09-30	Annual 2023 2023-12-31	Q3 2023 2023-09-30
Revenue	$144.33K	$0.00	$0.00	$0.00	$0.00
Operating Income	Not available	$-226.00M	$-160.38M	$-609.65M	$-573.44M
Net Income	Not available	$-221.31M	$-160.11M	$-614.93M	$-578.36M
EPS (Diluted)	$-0.29	$-0.31	$-0.22	$-0.99	$-0.98
Total Assets	Not available	$435.56M	$502.85M	$202.95M	$218.48M
Total Liabilities	Not available	$46.81M	$64.93M	$125.26M	$119.10M
Cash & Equivalents	Not available	$104.86M	$93.78M	$71.42M	$23.79M
Free Cash Flow OCF − CapEx	Not available	$-142.25M	$-93.56M	$-76.89M	$-57.43M
Shares Outstanding	Not available	737.63M	737.09M	701.66M	697.85M

Financial data is sourced from public SEC filings where available. Some metrics may be unavailable without premium market data. The amber (Est.) column shows Wall Street analyst consensus for the next reporting period — only Revenue and EPS are covered by published consensus, so other line items remain blank. These are third-party estimates, not company guidance.

Core line items from SMMT's most recent SEC filings (10-K / 10-Q via EDGAR XBRL). Last 4 reporting periods.

52w low +31.2%

Entity: Summit Therapeutics Inc.·Source: SEC EDGAR companyfacts·Next-Q consensus from Finnhub

Metric	Q3 2026 (Est.) Expected 2026-08-10	Annual 2024 2024-12-31	Q3 2024 2024-09-30	Annual 2023 2023-12-31	Q3 2023 2023-09-30
Revenue	$144.33K	$0.00	$0.00	$0.00	$0.00
Operating Income	Not available	$-226.00M	$-160.38M	$-609.65M	$-573.44M
Net Income	Not available	$-221.31M	$-160.11M	$-614.93M	$-578.36M
EPS (Diluted)	$-0.29	$-0.31	$-0.22	$-0.99	$-0.98
Total Assets	Not available	$435.56M	$502.85M	$202.95M	$218.48M
Total Liabilities	Not available	$46.81M	$64.93M	$125.26M	$119.10M
Cash & Equivalents	Not available	$104.86M	$93.78M	$71.42M	$23.79M
Free Cash Flow OCF − CapEx	Not available	$-142.25M	$-93.56M	$-76.89M	$-57.43M
Shares Outstanding	Not available	737.63M	737.09M	701.66M	697.85M

Financial data is sourced from public SEC filings where available. Some metrics may be unavailable without premium market data. The amber (Est.) column shows Wall Street analyst consensus for the next reporting period — only Revenue and EPS are covered by published consensus, so other line items remain blank. These are third-party estimates, not company guidance.